alzheon, Author at Alzheon | Preserving Future Memories

About alzheon

This author has not yet filled in any details.
So far alzheon has created 208 blog entries.

10 Apr, 2025

Topline Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 in Patients with Early Alzheimer’s Disease Carrying Two Copies of APOE4 Gene

alzheon2025-04-09T19:45:03-04:00April 10th, 2025|

18 Mar, 2025

Alzheon to Present Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 at Dedicated Symposium at ADPD Conference in Vienna on April 1st, 2025

alzheon2025-03-14T11:11:08-04:00March 18th, 2025|

25 Feb, 2025

Alzheon Announces Two New Scientific Papers Ahead of APOLLOE4 Phase 3 Trial Topline Symposium at ADPD Conference in Vienna on April 1st, Marking 15 Pathbreaking Peer-Reviewed Publications from Alzheon

alzheon2025-02-23T13:49:33-05:00February 25th, 2025|

5 Feb, 2025

Clinical Pharmacokinetics of Oral ALZ-801/Valiltramiprosate in a 2-Year Phase 2 Trial of APOE4 Carriers with Early Alzheimer’s Disease

alzheon2025-04-13T16:04:23-04:00February 5th, 2025|

7 Jan, 2025

Alzheon Announces Appointment of Renowned Investor and Financial Executive Muneer A. Satter to Board of Directors

alzheon2025-01-03T09:31:33-05:00January 7th, 2025|

2 Jan, 2025

Could a single pill crack the code of treating Alzheimer’s disease?

alzheon2025-01-04T15:43:38-05:00January 2nd, 2025|

1 Jan, 2025

Point of view: Challenges in implementation of new immunotherapies for Alzheimer’s disease

alzheon2025-04-13T16:00:29-04:00January 1st, 2025|

18 Sep, 2024

New Peer-Reviewed Scientific Publication Describes Study Design and Baseline Characteristics from APOLLOE4 Phase 3 Trial of Oral ALZ-801/Valiltramiprosate in APOE4/4 Homozygous Individuals with Early Alzheimer’s Disease

alzheon2025-02-20T18:54:55-05:00September 18th, 2024|

13 Aug, 2024

APOLLOE4 Phase 3 study of oral ALZ-801/valiltramiprosate in APOE ε4/ε4 homozygotes with early Alzheimer’s disease: Trial design and baseline characteristics

alzheon2025-04-13T15:47:38-04:00August 13th, 2024|

23 Jul, 2024

Alzheon to Present Phase 2 Biomarker Trial Results and Baseline Characteristics from APOLLOE4 Phase 3 Trial of Oral ALZ-801/Valiltramiprosate in Patients with Early Alzheimer’s Disease at Alzheimer’s Association International Conference

alzheon2024-07-19T10:15:31-04:00July 23rd, 2024|